Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Exterior view of a Jean Coutu store on Nun's Island in Montreal, August 21, 2013.

Christinne Muschi/The Globe and Mail

Jean Coutu Group (PJC) Inc. says it plans to distribute up to $502-million to shareholders through a share buyback program as well as a one-time dividend of 50 cents.

The drugstore giant said it intends to buy back up to 22 million class A subordinate voting shares at $18.50 per share in addition to the 50-cent per class A and B share dividend following the sale of its equity stake in U.S. pharmacy chain Rite Aid Corp. and given its strong cash flow from operations.

Longueuil, Que.-based Coutu also said on Wednesday that it posted net profit of $49.9-million or 24 cents per share in the second quarter of fiscal 2014, compared with $50-million or 23 cents per share in the year-earlier period.

Story continues below advertisement

The 24-cents EPS missed analysts' consensus estimate of 25 cents.

Coutu said an increase in the number of generic drug prescriptions with lower selling prices than those for brand-name drugs hurt second-quarter retail sales.

The introduction of new generic drugs reduced pharmacy retail sales growth by 2.2 per cent and generic-drug price reductions trimmed the growth of those sales by 1.1 per cent, it said.

In the second quarter, 67.2 per cent of prescriptions were for generics, up from 61 per cent for the comparable period a year earlier, the company said.

Coutu and other drugstore chains are feeling growing pressure on their profit margins as a result of government-imposed price controls on generic drugs.

Including extraordinary items, net profit in the second quarter was $208.2-million or 99 cents – due mostly to gains of $158.3-million related to the Rite Aid investment -- compared with $51.2-million or 23 cents.

Revenue in the second quarter was $653.8-million, down from $658.7-million in the year-earlier period.

Story continues below advertisement

Coutu president and chief executive officer François Coutu said on a conference call Wednesday that the company continues to look for acquisition opportunities but that any deals would likely be more for independents than for entire chains or segments of chains.

The impact of generic drug reform on the more vulnerable independent players should help shake out some potential acquisition targets but there has not been much fallout so far, said Mr. Coutu.

"The dust hasn't settled yet. We'll be patient. I hope our shareholders as well are patient," he said.

The company said that philanthropic organization Fondation Marcelle et Jean Coutu plans to deposit 21 million shares for repurchase under the company's buyback offer.

The foundation is a trust controlled by Coutu founder Jean Coutu and his family.

The number of shares Coutu will ultimately purchase from the trust will depend on the number of shares deposited to Coutu's offer by other shareholders, the company said.

Story continues below advertisement

Pharmacy chains are under the gun to consolidate as the retail sector in Canada becomes more challenging with the entry into Canada of U.S. giants like Target Corp. and mergers such as that of Loblaw Cos. Ltd. with Shoppers Drug Mart.

"Jean Coutu does not have any outstanding debt and we believe that this distribution of capital demonstrates our commitment to our shareholders without constraining our growth plan for the corporation," Mr. Coutu said in a news release.

The company said the buyback offer expires Nov. 14, 2013 and that the special dividend will be paid on Dec. 2, 2013.

Coutu operates 411 franchised stores, mostly located in Quebec.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies